» Articles » PMID: 35764656

The Impact of Rare Germline Variants on Human Somatic Mutation Processes

Overview
Journal Nat Commun
Specialty Biology
Date 2022 Jun 28
PMID 35764656
Authors
Affiliations
Soon will be listed here.
Abstract

Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells.

Citing Articles

Mutational signature analyses in multi-child families reveal sources of age-related increases in human germline mutations.

Shojaeisaadi H, Schoenrock A, Meier M, Williams A, Norris J, Palmer N Commun Biol. 2024; 7(1):1451.

PMID: 39506086 PMC: 11541588. DOI: 10.1038/s42003-024-07140-2.


Germline functional variants contribute to somatic mutation and outcomes in neuroblastoma.

Seo E, Lee J, Lim J, Shin S, Cho H, Ju H Nat Commun. 2024; 15(1):8360.

PMID: 39333105 PMC: 11437149. DOI: 10.1038/s41467-024-52128-5.


Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes.

Attardi E, Tiberi L, Mattiuz G, Formicola D, Dirupo E, Raddi M Hemasphere. 2024; 8(7):e112.

PMID: 39015540 PMC: 11250510. DOI: 10.1002/hem3.112.


Co-expression in tissue-specific gene networks links genes in cancer-susceptibility loci to known somatic driver genes.

Urzua-Traslavina C, van Lieshout T, Boulogne F, Domanegg K, Zidan M, Bakker O BMC Med Genomics. 2024; 17(1):186.

PMID: 39010058 PMC: 11247850. DOI: 10.1186/s12920-024-01941-4.


Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes.

Cao X, Huber S, Ahari A, Traube F, Seifert M, Oakes C Genome Med. 2024; 16(1):70.

PMID: 38769532 PMC: 11103968. DOI: 10.1186/s13073-024-01331-6.


References
1.
Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Tomasetti C, Marchionni L, Nowak M, Parmigiani G, Vogelstein B . Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2014; 112(1):118-23. PMC: 4291633. DOI: 10.1073/pnas.1421839112. View

4.
Martincorena I, Raine K, Gerstung M, Dawson K, Haase K, Van Loo P . Universal Patterns of Selection in Cancer and Somatic Tissues. Cell. 2018; 173(7):1823. PMC: 6005233. DOI: 10.1016/j.cell.2018.06.001. View

5.
Helleday T . Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis. 2010; 31(6):955-60. DOI: 10.1093/carcin/bgq064. View